Porphyria cutanea tarda (PCT) is caused by an enzymatic defect in uroporphyrinogen decarboxylase, a component in heme biosynthesis. The resulting accumulation of porphyrins leads to skin symptoms: photosensitivity, vesicles, bullae, erosions, crusts, scars, and milia. Treatments include photoprotective clothing, sunscreens, therapeutic phlebotomy, and antimalarial medications. Slow infusion of subcutaneous desferrioxamine, an iron chelator, reduces iron stores in patients with PCT, but treatment is prolonged and cumbersome. In this prospective, open-label study, Pandya et al demonstrate that the oral iron-chelating agent deferasirox may be a useful, effective, and well-tolerated alternative to desferrioxamine.